Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: Role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer

Human Gene Therapy

Volumn 11, Issue 1, 2000, Pages 101-112

  De Geest, Bart ^a   Van Linthout, Sophie ^a   Lox, Marleen ^a   Collen, Désiré ^a   Holvoet, Paul ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA;

ADENOVIRUS; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENHANCER REGION; GENE EXPRESSION; GENE TRANSFER; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MOUSE; NONHUMAN; PROMOTER REGION;

ADENOVIRIDAE; ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; BASE SEQUENCE; CELL DIVISION; DNA PRIMERS; ENHANCER ELEMENTS (GENETICS); FEMALE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INTRONS; LIVER; MICE; MICE, INBRED C57BL; PROMOTER REGIONS (GENETICS); RECOMBINATION, GENETIC; T-LYMPHOCYTES;

EID: 0033982331     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050016193     Document Type: Article

References (35)

1. Benoit, P., Emmanuel, F., Caillaud, J.M., Bassinet, L., Castro, G., Gallix, P., Fruchart, J.C., Branellec, D., Denèfle, P., and Duverger, N. (1999). Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation 99, 105-110.
2. Bloomfield Rubins, H., Robins, S.J., Collins, D., Fye, C.L., Anderson, J.W., Elam, M.B., Faas, F.H., Linares, E., Schaefer, E.J., Schectman, G., Wilt, T., and Wittes, J. (1999). Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341, 410-418.
3. Carmeliet, P., Stassen, J.M., Van Vlaenderen, I., Meidell, R.S., Collen, D., and Gerard, R.D. (1997). Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice. Blood 90, 1527-1534.
4. Challita, P.M., and Kohn, D.B. (1994). Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc. Natl. Acad. Sci. U.S.A. 91, 2567-2571.
5. Chomczynski, P., and Sacchi, N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159.
6. Connelly, S., Gardner, J.M., McClelland, A., and Kaleko, M. (1996). High-level tissue-specific expression of functional human factor VIII in mice. Hum. Gene Ther. 7, 183-195.
7. De Geest, B., Zhao, Z., Collen, D., and Holvoet, P. (1997). Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. Circulation 96, 4349-4356.
8. Dreyfuss, G., Swanson, M.S., and Pinol Roma, S. (1988). Heterogeneous nuclear ribonucleoprotein particles and the pathway of mRNA formation. Trends Biochem. Sci. 13, 86-91.
9. Duverger, N., Kruth, H., Emmanuel, F., Caillaud, J.M., Viglietta, C., Castro, G., Tailleux, A., Fievet, C., Fruchart, J.C., Houdebine, L.M., and Denefle, P. (1996). Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 94, 713-717.
10. Emerman, M., and Temin, H.M. (1986). Quantitative analysis of gene suppression in integrated retrovirus vectors. Mol. Cell. Biol. 6, 792-800.
11. Gomez-Foix, A.M., Coats, W.S., Baque, S., Alam, T., Gerard, R.D., and Newgard, C.B. (1992). Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism. J. Biol. Chem. 267, 25129-25134.
12. Gordon, D.J., and Rifkind, B.M. (1989). High-density lipoprotein - the clinical implications of recent studies. N. Engl. J. Med. 321, 1311-1316.
13. Gordon, D.J., Probstfield, J.L., Garrison, R.J., Neaton, J.D., Castelli, W.P., Knoke, J.D., Jacobs, D.R., Jr., Bangdiwala, S., and Tyroler, H.A. (1989). High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79, 8-15.
14. Harms, J.S., and Splitter, G.A. (1995). Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum. Gene Ther. 6, 1291-1297.
15. Holvoet, P., Danloy, S., Deridder, E., Lox, M., Bernar, H., Dhoest, A., and Collen, D. (1998). Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice. J. Clin. Invest. 102, 379-385.
16. Januzzi, J.L., Azrolan, N., O'Connell, A., Aalto-Setala, K., and Breslow, J.L. (1992). Characterization of the mouse apolipoprotein Apoa-1/Apoc-3 gene locus: Genomic, mRNA, and protein sequences with comparisons to other species. Genomics 14, 1081-1088.
17. Kaleko, M., Garcia, J.V., and Miller, A.D. (1991). Persistent gene expression after retroviral gene transfer into liver cells in vivo. Hum. Gene Ther. 2, 27-32.
18. Kurachi, S., Hitomi, Y., Furukawa, M., and Kurachi, K. (1995). Role of intron I in expression of the human factor IX gene. J. Biol. Chem. 270, 5276-5281.
19. Liu, A.C., Lawn, R.M., Verstuyft, J.G., and Rubin, E.M. (1994). Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice. J. Lipid Res. 35, 2263-2267.
20. Manninen, V., Elo, M.O., Frick, M.H., Haapa, K., Heinonen, O.P., Heinsalmi, P., Helo, P., Huttunen, J.K., Kaitaniemi, P., Koskinen, P., et al. (1988). High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. JAMA 260, 641-651.
21. McGrory, W.J., Bautista, D.S., and Graham, F.L. (1988). A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 163, 614-617.
22. Michou, A.I., Santoro, L., Christ, M., Julliard, V., Pavirani, A., and Mehtali, M. (1997). Adenovirus-mediated gene transfer: Influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther. 4, 473-482.
23. Nakai, H., Herzog, R.W., Hagstrom, J.N., Walter, J., Kung, S.H., Yang, E.Y., Tai, S.J., Iwaki, Y., Kurtzman, G.J., Fisher, K.J., Colosi, P., Couto, L.B., and High, K.A. (1998). Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 91, 4600-4607.
24. National Heart, Lung and Blood Institute. (1990). Morbidity and Mortality Chartbook on Cardiovascular, Lung and Blood Diseases. (Department of Health and Human Services, Washington, D.C.).
25. Palmiter, R.D., Sandgren, E.P., Avarbock, M.R., Allen, D.D., and Brinster, R.L. (1991). Heterologous introns can enhance expression of transgenes in mice. Proc. Natl. Acad. Sci. U.S.A. 88, 478-482.
26. Paszty, C., Maeda, N., Verstuyft, J., and Rubin, E.M. (1994). Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J. Clin. Invest. 94, 899-903.
27. Plump, A.S., Scott, C.J., and Breslow, J.L. (1994). Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. U.S.A. 91, 9607-9611.
28. Qin, L., Ding, Y., Pahud, D.R., Robson, N.D., Shaked, A., and Bromberg, J.S. (1997). Promoter attenuation in gene therapy: Interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum. Gene Ther. 8, 1365-1374.
29. Rubin, E.M., Krauss, R.M., Spangler, E.A., Verstuyft, J.G., and Clift, S.M. (1991). Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature (London) 353, 265-267.
30. Schiedner, G., Morral, N., Parks, R.J., Wu, Y., Koopmans, S.C., Langston, C., Graham, F.L., Beaudet, A.L., and Kochanek, S. (1998). Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nature Genet. 18, 180-183.
31. Shachter, N.S., Zhu, Y., Walsh, A., Breslow, J.L., and Smith, J.D. (1993). Localization of a liver-specific enhancer in the apolipoprotein E/C-I/C-II gene locus. J. Lipid Res. 34, 1699-1707.
32. Shachter, N.S., Ebara, T., Ramakrishnan, R., Steiner, G., Breslow, J.L., Ginsberg, H.N., and Smith, J.D. (1996). Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein C-I. J. Clin. Invest. 98, 846-855.
33. Simonet, W.S., Bucay, N., Lauer, S.J., and Taylor, J.M. (1993). A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice. J. Biol. Chem. 268, 8221-8229.
34. Tripathy, S.K., Black, H.B., Goldwasser, E., and Leiden, J.M. (1996). Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med. 2, 545-550.
35. Worgall, S., Wolff, G., Falck-Pedersen, E., and Crystal, R.G. (1997). Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8, 37-44.